Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats schizophrenia and different types of behavior problems. Belongs to a class of drugs called phenothiazines.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 21 to 38 of 38

Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet]

We compared the effectiveness and harms of anticonvulsants, tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors (SNRIs), and the lidocaine patchin adults with neuropathic pain.

Drug Class Reviews - Oregon Health & Science University.

Version: June 2011
Show search results within this document

Depot bromperidol decanoate for schizophrenia

Bromperidol decanoate is used as a long‐acting antipsychotic medication in at least Belgium, Germany, Italy and the Netherlands. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. However, this older antipsychotic preparation has very few data from good quality studies and new trials are needed to fully understand the effects of this preparation.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

BACKGROUND: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Pharmacological management of Huntington's disease: an evidence-based review

INTRODUCTION: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evidence based review (EBR) of treatment studies has not yet been published.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Depot fluspirilene for schizophrenia

Schizophrenia is a serious, chronic and relapsing mental illness with a worldwide lifetime prevalence of about one percent. Antipsychotic drugs are the mainstay of treatment for schizophrenia, but compliance with medication is often poor due to the adverse effects profile of the drugs and/or the patient's beliefs about their illness. Non‐compliance with medication is a major cause of relapse with significant personal, social and economic costs.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients

The authors concluded that antipsychotic drugs are an effective and safe treatment of delirium in medically or surgically ill patients. Recommendations for specific agents are limited by the quality and quantity of the available data. The authors? conclusions reflect the evidence available but the included studies were small and had serious flaws, therefore these conclusions may not be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Penfluridol for schizophrenia

Synopsis pending.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Drug combinations for chronic neuropathic pain in adults

Neuropathic pain – due to nerve disease or damage – is often treated by pain medications which have limited effect and/or dose‐related side effects when given alone. Combinations of more than one drug are often used with the goal of achieving better pain relief or fewer side effects (if the pain relieving effects of the combined drugs are more additive than the side effects), or both. Despite evidence that over 45% of individuals suffering from neuropathic pain take two or more drugs for their pain, we could find only 21 high‐quality studies of various different systemic and topical drug combinations. Given the wide possible variety of different drug combinations and the small number of studies, results for neuropathic pain from this review are insufficient to suggest the value of any one specific drug combination. However, the publication of multiple high‐quality studies suggesting the superiority of some drug combinations, together with evidence that drug combinations are widely used in clinical practice, underline the importance of conducting more combination studies with improved methodology.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness [Internet]

Individuals with serious mental illness (SMI) have excess mortality from cardiovascular disease (CVD) and high rates of CVD risk factors such as diabetes, obesity, and hyperlipidemia. We conducted a systematic review to evaluate interventions to improve CVD risk factors in adults with SMI.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2013
Show search results within this document

First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness

In response to a request from the public about antipsychotics used to treat schizophrenia and bipolar disorder in adults (U.S. Food and Drug Administration-approved indications), a systematic review was undertaken to examine what is known about the comparative effectiveness, benefits, and adverse effects of these drugs. Studies of antipsychotics used in treating dementia, an off-label indication, were not included in the review. The systematic review included 114 clinical studies of schizophrenia and 12 studies of bipolar disorder published up to July 2011. The full report of research evidence is available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm. This is a summary of the full report. It is provided to inform discussions of options with patients and their caregivers and to assist in decisionmaking along with consideration of a patient’s values and preferences. Reviews of evidence should not be construed to represent clinical recommendations or guidelines.

Comparative Effectiveness Review Summary Guides for Clinicians [Internet] - Agency for Healthcare Research and Quality (US).

Version: April 10, 2013

Screening for Suicide Risk [Internet]

To review systematically the literature regarding whether screening for suicide risk in primary care results in decreased morbidity, mortality, or both.

Systematic Evidence Reviews - Agency for Healthcare Research and Quality (US).

Version: May 2004
Show search results within this document

Self-Harm: The Short-Term Physical and Psychological Management and Secondary Prevention of Self-Harm in Primary and Secondary Care

This guideline has been developed to advise on the short-term physical and psychological management and secondary prevention of self-harm in primary and secondary care. The guideline recommendations have been developed by a multidisciplinary group of healthcare professionals, patients and their representatives, and researchers after careful consideration of the best available evidence. It is intended that the guideline will be useful to clinicians and service commissioners in providing and planning high quality care for those people who self-harm while also emphasising the importance of the experience of care for service users and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2004
Show search results within this document

Suicide Prevention Interventions and Referral/Follow-Up Services: A Systematic Review [Internet]

Suicide is the tenth leading cause of death in the United States (US), with nearly 100 suicides occurring each day and over 36,000 dying by suicide each year. Among Veterans and current military, suicide is a national public health concern. Recent estimates suggest current or former military represent 20 percent of all known suicides in the US and the rate of suicides among Veterans utilizing Veterans Health Administration (VHA) services is estimated to be higher than the general population. The enormity of the problem has led to several major public health initiatives and a growth in research funding for suicide prevention.

Evidence-based Synthesis Program - Department of Veterans Affairs.

Version: March 2012
Show search results within this document

Nausea and Vomiting (PDQ®): Health Professional Version

Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 4, 2014

Pain in Patients with Polytrauma: A Systematic Review [Internet]

Polytrauma is defined in the VHA Polytrauma Rehabilitation Centers Directive dated June 8, 2005 as: “injury to the brain in addition to other body parts or systems resulting in physical, cognitive, psychological, or psychosocial impairments and functional disability.” The definition of polytrauma has since expanded to include concurrent injury to two or more body parts or systems that results in cognitive, physical, psychological or other psychosocial impairments. Traumatic Brain Injury (TBI) often occurs in polytrauma and in combination with other disabling conditions including amputation, auditory or visual impairments, spinal cord injury (SCI), post-traumatic stress disorder (PTSD), and other mental health conditions.

Evidence-based Synthesis Program - Department of Veterans Affairs (US).

Version: September 2008
Show search results within this document

Psychosis with Coexisting Substance Misuse: Assessment and Management in Adults and Young People

This clinical guideline covers the assessment and management of adults and young people (aged 14 years and older) who have a clinical diagnosis of psychosis (schizophrenia, bipolar disorder or other affective psychosis) and coexisting substance misuse (harmful use of any psychotropic substance including alcohol and legal or illicit drugs).

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2011
Show search results within this document

Family Involved Psychosocial Treatments for Adult Mental Health Conditions: A Review of the Evidence [Internet]

Since 2008, the President has signed two new laws expanding VA authority to provide family services for Veterans’ mental health care and creating a need to identify efficacious and promising family involved interventions for improving Veterans’ mental health outcomes. With one exception, prior reviews have traditionally focused on one condition at a time, limiting comparisons across conditions and preventing a synthesis of the evidence for all mental health conditions, including those with few randomized controlled trials (RCTs; e.g., Posttraumatic Stress Disorder or PTSD). Finally, prior reviews are potentially less relevant to VA populations due to their focus on studies conducted in non-Veteran populations.

Evidence-based Synthesis Program - Department of Veterans Affairs.

Version: February 2012
Show search results within this document

Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder

This guideline has been developed to advise on the identification, treatment and management of obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD). Although distinct disorders, OCD and BDD share a number of common features and there is a high degree of similarity between the treatments for the two conditions. The guideline recommendations have been developed by a multidisciplinary team of healthcare professionals, people with OCD, a carer and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to clinicians and service commissioners in providing and planning high quality care for those with OCD and BDD while also emphasising the importance of the experience of care for people with OCD, BDD, and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2006
Show search results within this document

Systematic Reviews in PubMed

See all (33)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...